Correvio Pharma Corp. - Ordinary Shares (Canada) (CORV): Price and Financial Metrics

Correvio Pharma Corp. - Ordinary Shares (Canada) (CORV): $0.42

0.00 (0.82%)

POWR Rating

Component Grades













CORV Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CORV is -39.13 -- better than merely 0.7% of US stocks.
  • CORV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.42% of US stocks.
  • In terms of volatility of its share price, CORV is more volatile than 98.69% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Correvio Pharma Corp are JE, SPN, AKRX, KODK, and GSKY.
  • CORV's SEC filings can be seen here. And to visit Correvio Pharma Corp's official web site, go to

CORV Stock Price Chart Interactive Chart >

Price chart for CORV

CORV Price/Volume Stats

Current price $0.42 52-week high $2.79
Prev. close $0.42 52-week low $0.21
Day low $0.42 Volume 3,759,100
Day high $0.42 Avg. volume 5,353,682
50-day MA $0.39 Dividend yield N/A
200-day MA $1.10 Market Cap 27.79M

Correvio Pharma Corp. - Ordinary Shares (Canada) (CORV) Company Bio

Correvio Pharma Corp. (Formerly Cardiome Pharma Corp.), a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. The company was founded in 1986 and is based in Vancouver, Canada.

CORV Latest News Stream

Event/Time News Detail
Loading, please wait...

CORV Latest Social Stream

Loading social stream, please wait...

View Full CORV Social Stream

Latest CORV News From Around the Web

Below are the latest news stories about Correvio Pharma Corp that investors may wish to consider to help them evaluate CORV as an investment opportunity.

Correvio Obtains Final Order for Plan of Arrangement

VANCOUVER , May 21, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") pursuant to which ADVANZ PHARMA, through its wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), has agreed to acquire all of the issued and outstanding shares of Correvio for a total purchase price of approximately US$76 million , which includes the repayment of certain Correvio indebtedness, as described in Correvio's information circular dated April 16, 2020 . The Arrangem...

Yahoo | May 21, 2020

Correvio Announces Results from Annual General and Special Meeting of Securityholders

VANCOUVER , May 15, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced the results of voting on matters considered at its annual general and special meeting (the "Meeting") of Correvio shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") which took place in a virtual format earlier today. At the Meeting, Securityholders were asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA").

Yahoo | May 15, 2020

Will Correvio Pharma (CORV) Report Negative Q1 Earnings? What You Should Know

Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 6, 2020

Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA

VANCOUVER , May 6, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, released a report (the "Glass Lewis Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.

Yahoo | May 6, 2020

Correvio Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19

Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has postponed the reporting of its financial statements and management discussion and analysis (the "2020 Disclosure") in respect of the first quarter ended March 31, 2020 beyond the previous expected date of May 15, 2020. The Company now expects to release its 2020 Disclosure on or before June 29, 2020, subject to the Company ceasing to be a reporting issuer prior to the filing deadline as a result of the Proposed Arrangement (as defined below).

Yahoo | May 4, 2020

Read More 'CORV' Stories Here

CORV Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -89.23%
5-year -91.34%
2020 0.00%
2019 -83.53%
2018 60.65%
2017 -43.84%
2016 -65.97%

Continue Researching CORV

Here are a few links from around the web to help you further your research on Correvio Pharma Corp's stock as an investment opportunity:

Correvio Pharma Corp (CORV) Stock Price | Nasdaq
Correvio Pharma Corp (CORV) Stock Quote, History and News - Yahoo Finance
Correvio Pharma Corp (CORV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9095 seconds.